TPCN2 and lip cancer: Carriage of TPCN2 rs3750965:GG was associated with a lower risk of developing malignant neoplasms of mesothelial and soft tissue (MS) (OR: 0.72, 95% CI: 0.53–0.97, P = 0.032*, vs. A/A); in contrast, it was associated with an increased risk of malignant neoplasms of the lip, oral cavity, and pharynx (OR: 1.25, 95% CI: 1.02–1.53, P = 0.0311* vs. A/A).